Safe use of perampanel in a carrier of variegate porphyria

Acute symptomatic seizures occur in 10–20% of patients with acute intermittent porphyria in relapse. There are rarer reports of porphyria in people with chronic epilepsy who are mostly drug resistant. The association between epilepsy and porphyria is unclear. Porphyria might be the cause of chronic symptomatic epilepsy (if so, this would be rare or frequently undiagnosed) or there might be a chance association, given that epilepsy is common. Nevertheless, in drug-resistant epilepsy, clinicians should consider metabolic causes such as the porphyrias, especially when the seizure frequency increases on higher doses of certain antiepileptic drugs. Acute porphyric attacks can be potentially fatal and are usually precipitated, in susceptible individuals, by exposure to commonly used drugs, including certain antiepileptic drugs. It is, therefore, important to determine the correct dose and safety of use of certain drugs in people with porphyria. Having diagnosed porphyria-related seizures, the patient will also need treatment of the porphyria itself; its management includes appropriate selection of a non-porphyrinogenic antiepileptic drug. Enzyme-inducing medications induce hepatic heme synthesis, which can exacerbate porphyria symptoms, or provoke acute attacks.